Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis

Inclusion Criteria: * Signed informed consent form * Aged 18 years or more * Confirmed HIV-1 infection as documented at any time prior to trial entry per national HIV testing procedures * ART naïve * For women of childbearing potential i.e. women of childbearing age who are not menopausal, or permanently sterilized (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy) or not refraining from sexual activity: negative urinary test for pregnancy and acceptance to use contraceptive methods * Confirmed or probable active TB disease of any location, except neurological (meningitis or encephalitis), according to the following criteria based on WHO updated definitions: * Bacteriologically confirmed pulmonary TB (PTB) or extrapulmonary TB (EPTB), e.g. TB with a biological specimen positive by smear microscopy, culture or nucleic acid amplification test (such as Xpert MTB/RIF). * Clinically diagnosed PTB or EPTB with typical histological evidence of TB (caseous or granulomatous) on biopsy specimen or positive urinary LAM test OR a significant improvement on TB treatment * Ongoing standard rifampin-containing TB treatment for ≤8 weeks at inclusion * For French patients, affiliation to a Social Security program Exclusion Criteria: * HIV-2 co-infection * Impaired hepatic function (icterus or ALT (SGPT) \> 5ULN) * Hemoglobin \< 6.5 g/dl * Creatinine clearance \<60ml/min (assessed by the Cockroft and Gault formula) * Mycobacterium tuberculosis strain resistant to rifampin (current or past history). * Neurological TB (meningitis or encephalitis) * Severe associated diseases requiring specific treatment (including all specific AIDS defining illnesses other than TB, and any severe sepsis) * Any condition which might, in the investigator's opinion, compromise the safety of treatment and/or patient's adherence to trial procedures including very severe TB-related clinical condition * Concomitant treatments including phenytoin or phenobarbital (compounds interacting with UGT1A1) * For HCV co-infected patients, need to start specific treatment for hepatitis during the trial duration * For women of childbearing potential: * Pregnancy or breastfeeding * Refusal to use a contraceptive method * Any history of ARV intake for prevention of mother to child transmission of HIV (pMTCT) * Subjects participating in another clinical trial evaluating therapies and including an exclusion period that is still in force during the screening phase * Person under guardianship, or deprived of freedom by a judicial or administrative decision